OBJECTIVES: Multiple myeloma (MM) is an incurable disease with an incidence of 4-7 new cases by 100.000 people. Nowadays a 20% of the yearly 15 news cases of MM are candidates to autologous stem cell transplant (ASCT). We have previously reported data on the cost per quality-adjusted-life-year (QALY) of the MM treatment in a group of patients submitted to ASCT. The present communication is an update of such information after the inclusion of more patients and a longer follow-up period. METHODS: An observational retrospective study was performed and included detailed clinical data from a transplanted cohort of patients with MM. All patients received bortezomib and/or lenalidomide/pomalidomide based treatments. Costs were evaluated from the payer’s perspective and included total drug costs and hospital admission costs. QALYs values were obtained from the CEA Registry of Tufts University. Four health states were considered: complete response (CR), partial response, stability and progressive disease. Time between state transitions was used to calculate QALYs for each patient. RESULTS: The study included 24 patients with a mean age of 61,9±7,1 years; 17 of them (Group 1) were followed during 4,4±0,6 years and 7 (Group 2) during 2,4±0,4 years. Global complete response rate one year after ASCT was 13/24 (54,2%), dropping to 8/20 (40%) and 4/17 (23,5%) at two and three years respectively. For the whole cohort the median of QALY’s cost was 61.847€ (IQ range:34.171-76.337). For patients with CR two years after ASCT, the median of QALY’s cost was 40.768€ (IQ range: 27.522-64262). For all other patients the median of QALY’s cost was 64.106€ (IQ range: 45.159-83.271). CONCLUSIONS: These results show that the actual costs of MM treatment using protocols that include bortezomib, lenalidomide and/or pomalidomide are above the 30.000-40.000€ threshold generally admitted in cost-effectiveness studies, including those with CR.